Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
8.450
-0.180 (-2.09%)
Streaming Delayed Price
Updated: 1:50 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nuvectis Pharma, Inc. - Common Stock
< Previous
1
2
3
Next >
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
December 17, 2025
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung...
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
November 25, 2025
Event scheduled for Tuesday, December 2nd at 8:00 AM ET
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 04, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
September 25, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
August 11, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
July 31, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
July 08, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
June 20, 2025
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)?
Via
News Direct
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
April 29, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
March 26, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
March 14, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
March 05, 2025
From
Market News Alerts
Via
Business Wire
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
March 04, 2025
Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University)
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
February 27, 2025
From
Market News Alerts
Via
Business Wire
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
February 07, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
February 04, 2025
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
December 10, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort
November 14, 2024
Via
AB Newswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
November 14, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
October 28, 2024
From
PESG Research
Via
Business Wire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
October 23, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 07, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
September 16, 2024
From
PESG Research
Via
Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
August 15, 2024
Via
AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
July 18, 2024
Via
AB Newswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
